Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate

Rhea-AI Summary

Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 117% year-over-year growth in orders for Q4 2020, concluding the year with a 96% increase in orders despite the challenges posed by COVID-19. The company anticipates Q4 revenue between $25.5 million and $26.5 million, with an Adjusted EBITDA estimate of $3.1 million to $4.1 million. Zynex's full-year revenue is projected to be $80 million to $81 million, up 76% to 78% from last year. The company also increased its sales force to over 500 reps, aiming for approximately 600 by year-end 2021.

Positive

• 117% year-over-year order growth in Q4 2020
• Full-year revenue estimate between $80 million and $81 million, up 76%-78% from last year
• Q4 Adjusted EBITDA estimate increased to $3.1 million - $4.1 million, up from previous estimates
• Sales team expanded to over 500 representatives, targeting 600 by end of 2021

Negative

• None.

ENGLEWOOD, Colo., Jan. 12, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2020.

Thomas Sandgaard, CEO of Zynex said: "We concluded 2020 with strong orders and posted 117% year over year growth. For the full year orders grew 96% which in the midst of a pandemic is a very solid result. Our sales team continues to do a great job as they deal with unforeseen challenges brought about by COVID-19.

During Q4, we continued to aggressively hire sales reps as we exceeded 500 sales reps at year-end. We expect to have approximately 600 sales reps in the U.S. by the end of 2021.

The Company is confirming its previous revenue estimate for the fourth quarter of 2020 of between $25.5 and $26.5 million and is increasing its fourth quarter Adjusted EBITDA estimate to between $3.1 and $4.1 million. The previous estimate was between $2.3 and $3.3 million.

The Company's full year 2020 revenue estimate is between $80 and $81 million. The revenue estimate is approximately 76% to 78% above last year's full year revenue of $45.5 million.

2020 full year estimated Adjusted EBITDA is estimated between $13.3 to $14.3 million which is 10% to 18% above 2019's full year Adjusted EBITDA of $12.1 million.

Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to add additional sales reps in territories throughout the U.S. that we have not covered previously.

We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

About Zynex 

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.  For additional information, please visit: Zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements.  The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
Zynex, Inc.
(800) 495-6670

Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-announces-117-year-over-year-order-growth-and-increases-adjusted-ebitda-estimate-301206351.html

SOURCE Zynex

FAQ

What is Zynex's order growth rate for Q4 2020?

Zynex reported a 117% year-over-year growth in orders for Q4 2020.

What is the expected revenue range for Zynex in Q4 2020?

Zynex expects Q4 2020 revenue to be between $25.5 million and $26.5 million.

How much did Zynex's full-year revenue grow compared to last year?

Zynex's full-year revenue is projected to be 76% to 78% higher than last year's revenue of $45.5 million.

What is the adjusted EBITDA estimate for Zynex in Q4 2020?

The adjusted EBITDA estimate for Q4 2020 is between $3.1 million and $4.1 million.

How many sales representatives does Zynex plan to have by the end of 2021?

Zynex aims to have approximately 600 sales representatives in the U.S. by the end of 2021.